Basic Information
| LncRNA/CircRNA Name | LINC01638 |
| Synonyms | NA |
| Region | GRCh38_22:27221349-27224727 |
| Ensemble | ENSG00000233521 |
| Refseq | NM_001350812 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal adenocarcinoma |
| ICD-0-3 | NA |
| Methods | qRT-PCR , Western blot , in vitro knockdown etc. |
| Sample | colorectal adenocarcinoma patient's blood ,human colorectal adenocarcinoma cell lines (WiDr and HT-29) |
| Expression Pattern | up-regulated |
| Function Description | LINC01638 in plasma was upregulated in colorectal adenocarcinoma patients compared to healthy controls. Plasma levels of LINC01638 were affected by tumor size but not by distant metastasis.Plasma levels of RUNX2 were also higher in colorectal adenocarcinoma patients than in healthy controls, and were positively correlated with plasma levels of LINC01638 in colorectal adenocarcinoma patients but not in healthy controls.Upregulation of LINC01638 distinguished colorectal adenocarcinoma at stage I and II from healthy controls.LINC01638 shRNA knockdown led to RUNX2 downregulation, while RUNX2 overexpression exhibited no significant effects on LINC01638. LINC01638 silencing may inhibit cancer cell proliferation in colorectal adenocarcinoma through its interaction with RUNX2. |
| Pubmed ID | 31059049 |
| Year | 2019 |
| Title | LINC01638 Silencing Inhibits Cancer Cell Proliferation in Colorectal Adenocarcinoma Through Interaction With RUNX2 |
External Links
| Links for LINC01638 | GenBank HGNC NONCODE |
| Links for colorectal adenocarcinoma | OMIM COSMIC |